Autoantibodies against proteins of the telomeres — the protective caps of chromosomes and a marker of lifespan — were found in scleroderma patients with lung disease and shorter telomeres, a new study reveals. The findings suggest these autoantibodies could serve as a novel biomarker for scleroderma with lung disease.
Cantargia‘s antibody CAN10, intended to treat people with scleroderma and myocarditis, will be produced by BioInvent under the terms of a new manufacturing agreement, the two companies announced. The investigational therapy is currently in preclinical studies. Cantargia hopes to launch a Phase 1 clinical trial in early 2022,…
Proteins involved in scarring and the escape of immune cells from blood vessels towards nearby tissues are found at high levels in people with diffuse cutaneous systemic sclerosis (dcSSc), a new study reports. The findings also revealed that greater levels of specific proteins correlated with more severe thickening of…
Elevated blood levels of a protein called galectin-3 can help diagnose people with rheumatic diseases that include scleroderma, rheumatoid arthritis, and systemic lupus erythematosus, a study suggests. The study, “Diagnostic Power of Galectin-3 in Rheumatic Diseases,” was published in the Journal of Clinical Medicine. Chronic inflammation…
Elevated blood levels of the S100A12 protein, a type of danger signal released by skin cells, may contribute to skin scarring and interstitial lung disease (ILD) in people with scleroderma, a study suggests. The study, “Serum S100A12 levels: Possible association with skin sclerosis and interstitial…
Using a computer-based analysis to profile gene activity in blood samples may help identify the severe scleroderma patients who are most likely to respond to a stem cell transplant, a study suggests. That, in turn, will ultimately lead to better outcomes and faster improvement post-transplant for those who…
A Phase 3 trial testing iloprost, known as CIVI030, for the treatment of Raynaud’s phenomenon due to scleroderma has resumed patient enrollment, according to the therapy’s developer, CiVi Biopharma. The trial (NCT04040322), named AURORA and sponsored by Civi’s subsidiary Eicos Sciences, launched…
A new computer software, called Capillary.io, uses artificial intelligence (AI) to aid in diagnosing scleroderma at early disease stages. The tool, developed in partnership with the Sociedad Española de Medicina Interna (SEMI), was designed specifically to improve a non-invasive, highly sensitive and inexpensive technique — called nailfold capillaroscopy — used by…
Muscular involvement is linked with more severe symptoms in people with scleroderma, affecting heart, lungs and the digestive system, a study from China reports. These patients are likely to have a worse disease prognosis and poorer survival, its data show. The study “Myopathy is a Risk Factor for…
Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with diffuse cutaneous scleroderma (dcSSc), top-line data from a Phase 3 trial show. Participants given a placebo on top of immunosuppressants experienced an unprecedented improvement, Corbus Pharmaceuticals said in…
Get regular updates to your inbox.